Market Overview

UPDATE: Piper Jaffray Reiterates Overweight Rating, Raises PT on Isis Pharmaceuticals

Related ISIS
Isis Pharmaceuticals Earns $4M from Achaogen For The Initiation Of A Phase 3 Study Of Plazomicin
How Raytheon Company And General Dynamics Corporation Could Benefit From The ISIL Announcement
Making Money With Charles Payne: 08/29/14 (Fox Business)

In a report published Wednesday, Piper Jaffray & Co. reiterated its Overweight rating on Isis Pharmaceuticals (NASDAQ: ISIS), and raised its price target from $15.00 to $18.00.

Piper Jaffray noted, “ISIS is the leading antisense company with a rich pipeline of drugs in development. The primary driver for ISIS shares remains KYNAMRO with European approval this year and a January 29, 2013 PDUFA date. While ISIS shares have risen considerably since May 1st, we look for continued upside driven by KYNAMRO approval, clinical data read-outs and new partnerships. ISIS remains a Top Pick for 2H:12.”

Isis Pharmaceuticals closed Tuesday at $13.74.

Latest Ratings for ISIS

DateFirmActionFromTo
Aug 2014BMO CapitalMaintainsOutperform
Aug 2014Laidlow & Co.Initiates Coverage onBuy
May 2014JP MorganMaintainsNeutral

View More Analyst Ratings for ISIS
View the Latest Analyst Ratings

Posted-In: Piper Jaffray & Co.Analyst Color Price Target Analyst Ratings

 

Related Articles (ISIS)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters